Adding ACE inhibitors or ARBs to standard therapy for stable ischemic heart disease.
نویسنده
چکیده
Evidence-Based Answer Adding an ACE inhibitor to standard therapy reduces total mortality and cardiovascular events. Adding an ARB also reduces cardiovascular events. Overall effects are modest. Current evidence does not support the use of ACE inhibitor and ARB combinations over ACE inhibitors alone, because the risk of adverse events increases without additional benefit. Evidence suggests that adding ACE inhibitors or ARBs close to revascularization increases the risk of subsequent revascularization and hypotension. There were insufficient data to determine differences in effectiveness among specific ACE inhibitors and ARBs. (Strength of Recommendation: A, based on consistent, good-quality patientoriented evidence.)
منابع مشابه
Meta-Analysis of Combined Therapy with Angiotensin Receptor Antagonists versus ACE Inhibitors Alone in Patients with Heart Failure
BACKGROUND There is insufficient evidence whether the benefit of adding angiotensin II receptor blockers (ARBs) to angiotensin-converting enzyme (ACE) inhibitors outweighs the increased risk of adverse effects in patients with heart failure. METHODOLOGY/PRINCIPAL FINDINGS Two independent reviewers searched and abstracted randomized controlled trials of ARBs and ACE inhibitors compared to ACE ...
متن کاملRisk-treatment mismatch in the pharmacotherapy of heart failure.
CONTEXT Patients with heart failure have a wide spectrum of mortality risks. To maximize the benefit of available pharmacotherapies, patients with high mortality risk should receive high rates of drug therapy. OBJECTIVE To examine patterns of drug therapy and underlying mortality risk in patients with heart failure. DESIGN, SETTING, AND PATIENTS In the Enhanced Feedback for Effective Cardia...
متن کاملShould all patients at high cardiovascular risk receive renin-angiotensin system blockers?
Despite considerable advances in preventative treatment during the last two decades, the increasing burden of cardiovascular (CV) disease constitutes an urgent need for new therapeutic strategies to reduce CV mortality and morbidity in patients at high CV risk. Activation of the renin-angiotensin system (RAS) results in vasoconstrictive, proliferative and pro-inflammatory effects that contribut...
متن کاملSpironolactone and Chf
• Objective: To assess the impact of interventions to increase the use of spironolactone in patients with congestive heart failure (CHF) due to ventricular systolic dysfunction. • Methods: Charts of patients admitted to the medicine department of a single hospital with a primary diagnosis of class IV CHF and left ventricular ejection fraction of 40% or less were randomly selected and reviewed. ...
متن کاملRenin–angiotensin blockade in heart failure with preserved ejection fraction: a systematic review and meta‐analysis
Studies with angiotensin-converting enzyme inhibitors (ACE-Is) and angiotensin receptor blockers (ARBs) in patients with heart failure with preserved ejection fraction (HFpEF) have yielded inconsistent results. To conduct a systematic review and meta-analysis of all evidence for ACE-I and ARBs in patients with HFpEF, we searched PubMed, Ovid SP, Embase, and Cochrane database to identify randomi...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
- American family physician
دوره 86 1 شماره
صفحات -
تاریخ انتشار 2012